- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 45
- States / cities
- Fort Smith, Arkansas • La Jolla, California • Los Angeles, California + 33 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1873–1896
of 12,560
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Islet transplant, Antithymocyte globulin, Basiliximab, Lisofylline, Sirolimus, Tacrolimus
- Procedure · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Miami, Florida • Chicago, Illinois
- Conditions
- HIV-1 Infection
- Interventions
- FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 79
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more
- Conditions
- HIV Infection
- Interventions
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, Dolutegravir (DTG), VRC07-523LS
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 48 Hours
- Enrollment
- 1,120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2031
- U.S. locations
- 21
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 13 more
- Conditions
- Parkinson's Disease (PD)
- Interventions
- ABBV-951
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 41 more
- Conditions
- Prostate Cancer
- Interventions
- Lenalidomide, Docetaxel, Prednisone, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,059 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 66
- States / cities
- Phoenix, Arizona • Sedona, Arizona • Tucson, Arizona + 61 more
- Conditions
- Contrast Enhancement in Magnetic Resonance Imaging
- Interventions
- BAY1747846
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Miami, Florida • Knoxville, Tennessee
- Conditions
- Prurigo Nodularis
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 22
- States / cities
- Fountain Valley, California • San Diego, California • Washington D.C., District of Columbia + 19 more
- Conditions
- Pulmonary Embolism
- Interventions
- Günther Tulip® Vena Cava Filter, Cook Celect® Vena Cava Filters
- Device
- Lead sponsor
- Cook Research Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 18 more
- Conditions
- Lymphoma
- Interventions
- Atezolizumab [TECENTRIQ], Obinutuzumab, Polatuzumab Vedotin, Rituximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Miami, Florida • Stony Brook, New York + 2 more
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more
- Conditions
- Cardiac Failure, Myocardial Failure
- Interventions
- BMS-986224
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Saxagliptin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 20
- States / cities
- Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more
- Conditions
- COVID-19
- Interventions
- PF-07321332, Placebo for PF-07321332, Placebo for Ritonavir, Ritonavir
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,954 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 64
- States / cities
- Pelham, Alabama • Tucson, Arizona • Fullerton, California + 36 more
- Conditions
- HIV-1 Infection
- Interventions
- RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 63
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more
- Conditions
- Sarcoma
- Interventions
- dactinomycin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, irinotecan hydrochloride, vincristine sulfate, conventional surgery, radiation therapy, filgrastim
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 49 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 143
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 118 more
- Conditions
- Pain
- Interventions
- Suzetrigine
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 14
- States / cities
- Anaheim, California • Bakersfield, California • Miami, Florida + 11 more
- Conditions
- Encephalitis, Japanese Encephalitis
- Interventions
- ChimeriVax-JE, Japanese Encephalitis vaccine, 0.9% Saline
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,004 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 16
- States / cities
- Burbank, California • Costa Mesa, California • Davis, California + 13 more
- Conditions
- Eosinophilic Gastritis, Eosinophilic Duodenitis
- Interventions
- AK002, Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 70 more
- Conditions
- Primary Generalized Epilepsy
- Interventions
- Cenobamate, Placebo
- Drug
- Lead sponsor
- SK Life Science, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Tuscon, Arizona • Fresno, California + 37 more
- Conditions
- Asthma
- Interventions
- lebrikizumab, placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 62
- States / cities
- Oxford, Alabama • Long Beach, California • Los Angeles, California + 57 more
- Conditions
- Heart Failure, Hyperkalemia
- Interventions
- Not listed
- Lead sponsor
- Vifor (International) Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 52
- States / cities
- Little Rock, Arkansas • La Jolla, California • Northridge, California + 46 more
- Conditions
- Hypercholesterolemia
- Interventions
- Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
- Conditions
- Morning Sickness
- Interventions
- Bonjesta, Placebo
- Drug
- Lead sponsor
- Duchesnay Inc.
- Industry
- Eligibility
- 12 Years to 17 Years · Female only
- Enrollment
- 274 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Burbank, California • Hialeah, Florida • Miami, Florida + 7 more